Company intelligence / Profile preview

MDG Bio

San Francisco, California, USA

Ownership: Private
Employees: ~10
Development stage: Other

Overview

MDG Bio is a biotechnology company specializing in the development and commercialization of advanced molecular diagnostic solutions. The company focuses on providing high-accuracy testing for infectious diseases and oncology through its proprietary molecular diagnostic platform. MDG Bio's products are designed to improve patient outcomes by enabling rapid and precise detection of pathogens and genetic markers. The company serves clinical laboratories, hospitals, and research institutions globally. Its portfolio includes PCR-based kits and next-generation sequencing (NGS) services designed to streamline clinical workflows and improve diagnostic accuracy.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Molecular diagnosticsPCRNext-generation sequencing
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on MDG Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDG Bio.

Explore the full profile